TIDMOCTP
RNS Number : 5005T
Oxford Cannabinoid Tech.Holdings
24 November 2021
Oxford Cannabinoid Technologies Holdings plc
Results of Annual General Meeting
Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the
"Company"), the holding company of Oxford Cannabinoid Technologies
Ltd ("OCT"), (together, the "Group"), a company developing licensed
prescription cannabinoid medicines for approval by regulatory
agencies worldwide and targeting the U$ multi-billion pain market,
announces that all of the resolutions set out in the notice of
Annual General Meeting dated 27 October 2021 were duly passed at
today's Annual General Meeting.
Resolution For (including % Against % Total % of Withheld*
discretionary) ISC
voted
Receive
and adopt
the 2021
Annual Report
1. and Accounts 434,161,471 100.00% 4,711 0.00% 434,166,182 45.21% 10,669
-------------------- ---------------- -------- ------- ------- ----------
Approve
the Directors'
Remuneration
2. Report 415,591,935 96.31% 15,935,441 3.69% 431,527,376 44.93% 2,649,475
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Charanjit
3. Cheryl Dhillon 409,190,649 94.25% 24,973,423 5.75% 434,164,072 45.21% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
4. Karen Lowe 434,159,361 100.00% 4,711 0.00% 434,164,072 45.21% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Dr. John
5. Lucas 409,192,759 94.25% 24,973,423 5.75% 434,166,182 45.21% 10,669
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Indraneil
6. Mahapatra 356,013,210 82.00% 78,150,862 18.00% 434,164,072 45.21% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Bishrut
7. Mukherjee 330,983,856 76.23% 103,180,216 23.77% 434,164,072 45.21% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Julie Patricia
8. Pomeroy 409,122,643 94.23% 25,034,065 5.77% 434,156,708 45.21% 20,143
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Gavin Hilary
9. Sathianathan 354,174,790 99.48% 1,843,131 0.52% 356,017,921 37.07% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-elect
Clarissa
10. Ann Sowemimo-Coker 409,190,649 94.25% 24,973,423 5.75% 434,164,072 45.21% 12,779
-------------------- ---------------- -------- ------- ------- ----------
Re-appoint
Moore Kingston
Smith LLP
11. as auditor 434,161,471 100.00% 4,711 0.00% 434,166,182 45.21% 10,669
-------------------- ---------------- -------- ------- ------- ----------
Authorise
the Directors
to fix the
auditor's
12. remuneration 434,081,048 99.98% 85,134 0.02% 434,166,182 45.21% 10,669
-------------------- ---------------- -------- ------- ------- ----------
To authorise
the Directors
to allot
ordinary
shares or
grant rights
to subscribe
for or to
convert
any security
into ordinary
shares,
pursuant
to Section
551 of the
Companies
13. Act 2006. 415,576,695 95.72% 18,589,487 4.28% 434,166,182 45.21% 10,669
-------------------- ---------------- -------- ------- ------- ----------
To authorise
the Directors
to disapply
pre-emption
rights (general
14. authority).** 415,479,418 95.70% 18,667,400 4.30% 434,146,818 45.20% 30,033
-------------------- ---------------- -------- ------- ------- ----------
To authorise
the Directors
to disapply
pre-emption
rights (additional
15. authority).** 415,545,060 95.71% 18,609,122 4.29% 434,154,182 45.20% 22,669
-------------------- ---------------- -------- ------- ------- ----------
That a general
meeting
other than
an annual
general
meeting
may be called
on not less
than 14
clear days'
16. notice.** 433,954,746 99.97% 126,436 0.03% 434,081,182 45.20% 95,669
-------------------- ---------------- -------- ------- ------- ----------
* A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes "For" or "Against" a
resolution.
** Indicates special resolutions requiring a 75% majority.
Given that all resolutions passed concern ordinary business, no
submission will be made to the National Storage Mechanism in
accordance with Listing Rule 14.3.6R(2).
A copy of the Annual General Meeting results will be available
on the Company's website at
https://www.oxcantech.com/investor-financial-results-centre
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a
pharmaceutical company developing prescription cannabinoid
medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together
the "Group"). Cannabinoids are compounds found in the cannabis
plant that have been shown to have a range of therapeutic effects
on the body, including pain relief. The Group has a clearly defined
path to commercialisation, revenues and growth.
The Group is developing drug candidates through clinical trials
to gain regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with pre-clinical trials scheduled for 2022. The
Group's product pipeline also uses a balanced drug product strategy
that employs phytocannabinoids, cannabinoid derivatives and other
novel compounds for the treatment of pain.
OCTP operates a partnership model with external academic and
commercial partners, including the University of Oxford.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUSOVRAAUAUAA
(END) Dow Jones Newswires
November 24, 2021 10:35 ET (15:35 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Apr 2023 to Apr 2024
